Drugplain

ROMVIMZA 30 mg/1

Vimseltinib · CAPSULE · Deciphera Pharmaceuticals, LLC

No Recall History
Plain English

ROMVIMZA is a capsule containing vimseltinib at 30 mg/1, taken oral. Manufactured by Deciphera Pharmaceuticals, LLC.

Key Facts

Brand Name
ROMVIMZA
Generic Name
Vimseltinib
NDC Code (Product)
73207-304
Manufacturer
Deciphera Pharmaceuticals, LLC
Strength
30 mg/1
Dosage Form
CAPSULE
Route
ORAL
Marketing Status
Application #
NDA219304
Drug Class
Kinase Inhibitor [EPC]
Marketing Start
02/14/2025

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

fatigue111 reports
swelling face59 reports
periorbital swelling50 reports
pruritus47 reports
peripheral swelling44 reports
headache35 reports
eye swelling34 reports
nausea33 reports
product use issue33 reports
rash31 reports

Frequently Asked Questions

What is ROMVIMZA used for?

ROMVIMZA contains Vimseltinib. It is a capsule taken oral. Consult your doctor for specific uses.

Is ROMVIMZA a controlled substance?

ROMVIMZA is not classified as a controlled substance by the DEA.

What is the generic name for ROMVIMZA?

The generic name for ROMVIMZA is Vimseltinib. There are no other listed brand versions of Vimseltinib.

What is the NDC code for ROMVIMZA 30 mg/1?

The NDC (National Drug Code) for ROMVIMZA 30 mg/1 is 73207-304, listed by Deciphera Pharmaceuticals, LLC.

Product NDC

73207-304

Package NDC

73207-304-40

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)